• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Third party research

Generic: Inera deal sets up exciting 2024 - ABG

Generic Sweden

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
We expect a solid Q3 with 12% organic sales growth
15% EBIT growth y-o-y in Q3e
Inera framework agreement behind our revisions


Q3e: gradual recovery to continue

Generic has historically showed a stable development that stems from a recurring SaaS offering coupled with low churn in its client base. We see no reason to think this will not continue in the short term and therefore see another solid quarter in Q3e, with slightly higher sales growth q-o-q from a gradual recovery since the Q1 report (which had a lower growth rate). We expect 12% organic sales growth in Q3e, with better profitability, leading to 15% EBIT growth y-o-y.